Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Galectin Therapeutics
(NASDAQ:GALT)
Intraday
$3.25
0.01
[0.31%]
After-Hours
$3.25
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$3.25
0.01
[0.31%]
At close: May 9
$3.25
0
[0.00%]
After Hours: 5:26PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Galectin Therapeutics Stock (NASDAQ:GALT)
Galectin Therapeutics Stock (NASDAQ: GALT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 23, 2024
Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
Avi Kapoor
-
Apr 23, 2024, 6:53AM
Tuesday, April 09, 2024
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk
-
Apr 9, 2024, 11:57AM
Galectin Therapeutics Highlights Outcome Of Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study
Benzinga Newsdesk
-
Apr 9, 2024, 9:26AM
Friday, April 05, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Apr 5, 2024, 12:31PM
Monday, April 01, 2024
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk
-
Apr 1, 2024, 12:21PM
Monday, November 13, 2023
Galectin Therapeutics: Q3 Earnings Insights
Benzinga Insights
-
Nov 13, 2023, 8:50AM
Galectin Therapeutics' $20.4M Of Cash And Cash Equivalents And $30M Remaining Available Under A $60M Line Of Credit Provided By Its Chairman Is Sufficient Cash To Fund Currently Planned Operations And R&D Activities Through At Least December 31, 2024
Benzinga Newsdesk
-
Nov 13, 2023, 8:23AM
Galectin Therapeutics Q3 EPS $(0.24) Misses $(0.16) Estimate;
Benzinga Newsdesk
-
Nov 13, 2023, 8:23AM
Tuesday, October 03, 2023
Galectin Therapeutics Reports The Outcome Of The Fourth Data And Safety Monitoring Board Meeting For NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin In Patients With Portal Hypertension Caused By Non-Alcoholic SteatoHepatitis Live
Benzinga Newsdesk
-
Oct 3, 2023, 8:02AM
Tuesday, September 26, 2023
Galectin Therapeutics To Present Update On Its Belapectin Liver Cirrhosis Program At The 20th Edition Of Discovery On Target Meeting, In Boston, September 25-28, 2023
Benzinga Newsdesk
-
Sep 26, 2023, 8:07AM
Tuesday, August 15, 2023
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk
-
Aug 15, 2023, 7:17AM
Monday, August 14, 2023
Galectin Therapeutics Q2 EPS $(0.15) Beats $(0.21) Estimate
Happy Mohamed
-
Aug 14, 2023, 8:21AM
Friday, July 21, 2023
Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
Lisa Levin
-
Jul 21, 2023, 7:24AM
Wednesday, May 17, 2023
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk
-
May 17, 2023, 6:25AM
Monday, May 15, 2023
Galectin Therapeutics Q1 EPS $(0.19) Beats $(0.21) Estimate; The Company Had $17.8 Million Of Cash And Cash Equivalents, And Expects That It Will Require More Cash To Fund Operations After December 31, 2024
Benzinga Newsdesk
-
May 15, 2023, 8:18AM
Thursday, March 30, 2023
Galectin Therapeutics Reports FY22 EPS Loss Of (0.65), Down From $(0.52) Loss A Year Ago
Benzinga Newsdesk
-
Mar 30, 2023, 7:59AM
Thursday, March 16, 2023
Galectin Therapeutics Reported The Outcome Of Its Third Data And Safety Monitoring Board Meeting For NAVIGATE Phase 2B/3 Study Of Belapectin For Liver Cirrhosis Caused By NASH, Interim Data From The Phase 2B Portion Is Expected In Q4 Of 2024
Benzinga Newsdesk
-
Mar 16, 2023, 8:08AM
Friday, March 03, 2023
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk
-
Mar 3, 2023, 11:50AM
Thursday, March 02, 2023
Galectin Therapeutics Provides Final Randomization Status Of NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
Happy Mohamed
-
Mar 2, 2023, 8:27AM
Wednesday, February 22, 2023
$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying
Lisa Levin
-
Feb 22, 2023, 8:40AM
Tuesday, February 07, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Feb 7, 2023, 12:31PM
Tuesday, January 24, 2023
Galectin Therapeutics Contribution To Improve Histology Interpretation Of Cirrhotic Liver Biopsies With Machine Learning Published In Prominent Gastroenterology Journal
Benzinga Newsdesk
-
Jan 24, 2023, 8:12AM
Thursday, January 05, 2023
Galectin Therapeutics Announces The End Of Enrollment Of Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-alcoholic Steatohepatitis
Benzinga Newsdesk
-
Jan 5, 2023, 7:58AM
Monday, November 14, 2022
Galectin Therapeutics Q3 EPS $(0.14), Same YoY
Benzinga Newsdesk
-
Nov 14, 2022, 7:58AM
Wednesday, October 12, 2022
Galectin Therapeutics Receives FDA Approval To Proceed With Combination Immunotherapy Trial In Head And Neck Cancer
Bill Haddad
-
Oct 12, 2022, 7:54AM
Thursday, October 06, 2022
Galectin Therapeutics Reports The Outcome Of The Second Data And Safety Monitoring Board Meeting For NAVIGATE Phase 2b/3 Study Of Belapectin; DSMB Concluded That Navigate Can Continue As Designed, Without Modifications
Bill Haddad
-
Oct 6, 2022, 7:57AM
Thursday, September 29, 2022
CORRECTION: Correct Ticker For Galecto Is 'GLTO'
Benzinga Newsdesk
-
Sep 29, 2022, 6:05AM
Monday, August 15, 2022
Galectin Therapeutics Q2 EPS $(0.16) Down From $(0.15) YoY
Benzinga Newsdesk
-
Aug 15, 2022, 8:01AM
Monday, August 01, 2022
Around $30 Million Bet On This Communication Services Stock? 4 Penny Stocks Insiders Are Buying
Lisa Levin
-
Aug 1, 2022, 8:55AM
Friday, July 29, 2022
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Lisa Levin
-
Jul 29, 2022, 5:55AM
Wednesday, July 27, 2022
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Jul 27, 2022, 6:06PM
Tuesday, June 21, 2022
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations At The EASL International Liver Congress 2022
Benzinga Newsdesk
-
Jun 21, 2022, 8:00AM
Thursday, June 02, 2022
62 Biggest Movers From Yesterday
Lisa Levin
-
Jun 2, 2022, 6:10AM
Tuesday, May 24, 2022
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
May 24, 2022, 12:13PM
Tuesday, May 17, 2022
HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Lowers Price Target to $11
Benzinga Newsdesk
-
May 17, 2022, 7:17AM
Monday, May 16, 2022
Recap: Galectin Therapeutics Q1 Earnings
Benzinga Insights
-
May 16, 2022, 8:29AM
Galectin Therapeutics Q1 EPS $(0.17) Down From $(0.11) YoY
Benzinga Newsdesk
-
May 16, 2022, 8:09AM
Wednesday, May 11, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
May 11, 2022, 12:28PM
Wednesday, May 04, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
May 4, 2022, 12:29PM
Thursday, April 28, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Apr 28, 2022, 3:31PM
Thursday, April 14, 2022
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Apr 14, 2022, 5:48PM
Galectin Therapeutics Reports Outcome Of The First Data And Safety Monitoring Board For NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
Benzinga Newsdesk
-
Apr 14, 2022, 7:54AM
Monday, April 04, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Apr 4, 2022, 12:05PM
Friday, April 01, 2022
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Apr 1, 2022, 1:00PM
Thursday, March 31, 2022
Galectin Therapeutics: Q4 Earnings Insights
Benzinga Insights
-
Mar 31, 2022, 9:41AM
Galectin Therapeutics FY21 EPS $(0.52) vs $(0.41) In FY20
Benzinga Newsdesk
-
Mar 31, 2022, 8:10AM
Tuesday, March 29, 2022
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Mar 29, 2022, 11:43AM
Monday, December 13, 2021
Galectin Therapeutics Discusses Corporate Transformation, Progress Of NAVIGATE Trial And Outlines Strategy For Potential Phase 2 Cancer Immunotherapy Trial At Annual Meeting
Benzinga Newsdesk
-
Dec 13, 2021, 8:10AM
Friday, December 10, 2021
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Dec 10, 2021, 9:51AM
Monday, November 15, 2021
Galectin Therapeutics Q3 EPS $(0.14) Down From $(0.10) YoY
Luke J Jacobi
-
Nov 15, 2021, 8:08AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch